Cabozantinib shows promise as first line treatment for differentiated thyroid cancer

A kinase inhibitor called cabozantinib could be a viable therapy option for patients with metastatic, radioactive iodine-resistant thyroid cancer. In a recent trial tumors shrunk in 34 out of 35 patients who took the drug, and more than half of those patients saw the tumor size decrease by more than weiter …

Source:: https://www.sciencedaily.com/releases/2018/02/180213123249.htm

Kommentar verfassen